{"url_path":"/sec/nwbo/8-k/2026-07-20/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1072379/0001104659-26-084743-index.html","accession_number":"0001104659-26-084743","cik":"0001072379","ticker":"NWBO","issuer_name":"NORTHWEST BIOTHERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1072379/0001104659-26-084743-index.html","primary_entity_key":"0001072379","primary_entity_name":"NORTHWEST BIOTHERAPEUTICS INC"},"word_count":298,"has_tables":true,"body_markdown":"** **\n\n \n\n  \n\n \n\n \n\n \n\n**Item 7.01.**\n** Regulation FD Disclosure.**\n\n \n\nThe Company has received a number of\ninquiries about rumors that are circulating alleging that the Medicines and Healthcare Products Regulatory Agency (MHRA) has made a\ndecision on the Company’s Marketing Authorization Application (MAA) for DCVax-L for glioblastoma (GBM) and has rejected the\nMAA.\n\n \n\nWhile the Company’s\npolicy of not making interim reports on the MHRA process remains in place, to address these false rumors this morning the Company requested\nconfirmation from MHRA of the current status of the MAA. This afternoon, the MHRA confirmed the following:\n\n \n\n*“The Marketing Authorisation\nApplication submitted by Northwest Biotherapeutics, Inc. for DCVax-L (for glioblastoma) remains under its initial regulatory review,\nhas not been refused, withdrawn or appealed, and continues to progress towards a first regulatory decision.”*\n\n \n\nThe Company continues to\nhave constructive interactions with the MHRA, and the MAA remains under review.\n\n \n\nThe Company categorically\nrefutes the false rumors. The Company notes that such rumors appear to have intensified in the weeks since the Company presented at the\nBritish Neuro-Oncology Society (BNOS) Annual Meeting significant statistical data relating to the results of its Phase 3 trial of DCVax-L\nfor GBM. The Company believes that the rumors appear to be accompanied by various forms stock manipulation. The Company also believes\nthat the rumors may be part of such manipulation as the data in the BNOS presentation were quite encouraging. The Company believes it\nhas seen this pattern on a number of occasions following positive developments and news.\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of\nthe Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \nNORTHWEST BIOTHERAPEUTICS, INC.\n\n \n \n \n\nDate: July 17, 2026\nBy:\n/s/ Linda Powers\n\n \nName:\nLinda Powers\n\n \nTitle:\nChief Executive Officer and Chairman"}